

This listing will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-191. (Canceled)

192. (New) A method for modulating cell adhesion of cadherin-expressing cells comprising contacting the cells with a linear peptide comprising one or more of the cell adhesion recognition sequence, His-Ala-Val, wherein said linear peptide modulates cell adhesion.

193. (New) A method according to claim 192, wherein said linear peptide comprises a sequence selected from the group consisting of HAV, HAVHAV (SEQ ID NO: 10), SHAVSHAVSHAVS (SEQ ID NO: 11), LRAHAVDING (SEQ ID NO: 21), LRAHAVDVNG (SEQ ID NO: 22), MRAHAVDING (SEQ ID NO: 23), HLGAHAVDINGNQVET (SEQ ID NO: 24), FHLRAHAVDINGNQV (SEQ ID NO: 25), AHAVSE (SEQ ID NO: 27), AHAVDI (SEQ ID NO: 28), SHAVSS (SEQ ID NO: 29), LYSHAVSSNG (SEQ ID NO: 18), LFSHAVSSNG (SEQ ID NO: 19) and derivatives of the foregoing sequences having one or more C-terminal, N-terminal and/or side chain modifications.

194. (New) A method according to claim 192, wherein said linear peptide is linked to a targeting agent.

195. (New) A method according to claim 192, wherein said linear peptide further comprises at least one separate cell adhesion recognition sequence bound by an adhesion molecule other than a classical cadherin.

196. (New) A method according to claim 192, wherein said one or more of the cell adhesion recognition sequences, His-Ala-Val, are separated by a linker.

197. (New) A method according to claim 195, wherein said separate cell adhesion recognition sequence comprises a sequence selected from the group consisting of: RGD, YIGSR (SEQ ID NO: 12), KYSFNYDGSE (SEQ ID NO: 13), IWKHKGDRVILKKDVRF (SEQ ID NO: 14), YAT, FAT, YAS; RAL; GVNPTAQSSGSLYGSQIYALCNQFYTPAATGLYVDQYLYHYCVVDPQ E (SEQ ID NO: 15), QSSGSLYGSQ (SEQ ID NO: 16) and QYLYHYCVVD (SEQ ID NO: 17).

198. (New) A method according to claim 192, wherein said linear peptide is present within a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

199. (New) A method according to claim 198, wherein said pharmaceutical composition further comprises at least one separate cell adhesion recognition sequence bound by an adhesion molecule other than a classical cadherin.

200. (New) A method according to claim 199, wherein said separate cell adhesion recognition sequence comprises a sequence selected from the group consisting of: RGD, YIGSR (SEQ ID NO: 12), KYSFNYDGSE (SEQ ID NO: 13), IWKHKGDRVILKKDVRF (SEQ ID NO: 14), YAT, FAT, YAS; RAL; GVNPTAQSSGSLYGSQIYALCNQFYTPAATGLYVDQYLYHYCVVDPQ E (SEQ ID NO: 15), QSSGSLYGSQ (SEQ ID NO: 16) and QYLYHYCVVD (SEQ ID NO: 17).